PRUNE2 and prostate carcinoma: We found no significant differences in PRUNE2 expression across tumor stage, and only a small decrease in expression with increasing tumor grade, suggesting that loss of PRUNE2 tumor suppressor activity is an early molecular event in prostate cancer.